Ann D. Thor

Q: What Schools Are Affiliated With Ann D. Thor

Ann D. Thor is affiliated with the following schools: Poznań University of Medical Sciences, University of Oklahoma Health Sciences Center, University of Colorado Denver, Northwestern University, University of Colorado, Rush University, University of California, San Francisco, Duke University

Ann D. Thor's AcademicInfluence.com Rankings

Ann D. Thor

Philosophy

#9333

World Rank

#12873

Historical Rank

Logic

#6316

World Rank

#7825

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Ann D. Thor's Degrees

Doctorate Medicine Harvard University

Why Is Ann D. Thor Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ann D. Thor's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revision of the American Joint Committee on Cancer staging system for breast cancer. (2002) (1236)
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. (2000) (1104)
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. (1994) (979)
Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. (1994) (908)
Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. (1992) (810)
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. (1998) (625)
Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas (1996) (621)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008) (611)
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro (2009) (486)
Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. (1986) (467)
HER2 and response to paclitaxel in node-positive breast cancer. (2007) (433)
Metformin induces unique biological and molecular responses in triple negative breast cancer cells (2009) (399)
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide (2014) (317)
p53 gene mutations and protein accumulation in human ovarian cancer. (1993) (310)
Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. (2001) (305)
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. (2003) (291)
Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. (1994) (286)
The art and science of cytopathology: Richard M. DeMay, MD. Chicago IL, ASCP Press, 1996, 2 vol set, 1,289 pages, $285 (1996) (266)
Expression of ras oncogene p21 in prostate cancer. (1986) (265)
Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. (2006) (258)
Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors (1993) (249)
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. (2010) (236)
Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases (1984) (231)
Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. (1984) (225)
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. (2005) (221)
Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. (1988) (216)
The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. (1992) (215)
Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. (2004) (202)
Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. (1985) (200)
Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers (2012) (187)
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. (2000) (182)
The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. (1998) (181)
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. (2000) (180)
Ras oncogene mutations in benign and malignant thyroid neoplasms. (1991) (174)
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors (2010) (172)
HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer (1997) (169)
Invasive micropapillary carcinoma of the breast: a prognostic study. (1999) (167)
Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. (1991) (165)
Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody. (1985) (153)
Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. (1986) (149)
Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. (1999) (145)
A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation (2001) (145)
Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. (1986) (143)
Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells (2007) (143)
c-erbB-2 in breast cancer: development of a clinically useful marker. (2002) (137)
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions (2011) (136)
p53 abnormalities in human parathyroid carcinoma. (1994) (133)
Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. (1995) (132)
Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3 (1987) (131)
Monoclonal Antibody B72.3 Reactivity with Human Endometrium: A Study of Normal and Malignant Tissues (1987) (129)
pS2 expression and response to hormonal therapy in patients with advanced breast cancer. (1991) (128)
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. (2000) (124)
Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. (2001) (123)
Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. (2005) (122)
Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. (1989) (120)
Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. (1995) (119)
Age-associated biomarker profiles of human breast cancer. (2002) (116)
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. (2005) (114)
The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). (1986) (113)
ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues. (1986) (112)
Ovarian small cell carcinoma. Histogenetic considerations based on immunohistochemical and other findings. (1989) (110)
Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. (1985) (109)
Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. (1990) (108)
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. (2004) (108)
Glucose promotes breast cancer aggression and reduces metformin efficacy (2013) (106)
erbB-2 (HER-2) and Breast Cancer Progression (2003) (100)
Systemic Gene Delivery Expands the Repertoire of Effective Antiangiogenic Agents* (1999) (96)
Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. (2001) (87)
Ets regulation of the erbB2 promoter (2000) (87)
Metformin-Induced Killing of Triple-Negative Breast Cancer Cells Is Mediated by Reduction in Fatty Acid Synthase via miRNA-193b (2014) (85)
p53 mutations in benign breast tissue. (1995) (84)
Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. (1988) (82)
Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. (2002) (81)
Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. (1996) (79)
p53 gene analysis of ovarian borderline tumors and stage I carcinomas. (1995) (78)
Ovarian Endometrioid Carcinomas Resembling Sex Cord–Stromal Tumors. An Immunohistochemical Study (1989) (75)
Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens. (1986) (73)
p53 expression in ovarian borderline tumors and stage I carcinomas. (1994) (73)
Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. (2003) (72)
Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization. (1987) (70)
Metformin Selectively Targets Tumor-Initiating Cells in ErbB2-Overexpressing Breast Cancer Models (2013) (68)
Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling (2014) (68)
Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. (1984) (68)
Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. (1986) (66)
Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study (2004) (65)
Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer (2016) (63)
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. (2008) (62)
Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. (2012) (60)
Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. (1997) (60)
Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas. (1987) (56)
Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. (2009) (54)
Tumor‐associated glycoprotein (TAG‐72) detected in adenocarcinomas and benign lesions of the stomach (1986) (54)
Perinucleolar compartment prevalence has an independent prognostic value for breast cancer. (2005) (54)
Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice (2002) (52)
The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. (1994) (51)
Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells (2010) (51)
Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. (1993) (50)
Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression (2010) (50)
Histologic demonstration of antigens reactive with anti-p21 ras monoclonal antibody (RAP-5) in human stomach cancers. (1986) (48)
Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-α induced apoptosis (2006) (48)
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. (2009) (47)
Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial (2013) (47)
Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues. (1987) (45)
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer (2013) (45)
Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3. (1986) (45)
Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells (2005) (44)
Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family (2003) (43)
p21WAF1/CIP1 Expression in breast cancers: associations with p53 and outcome (2000) (42)
Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. (2010) (41)
Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. (2007) (41)
Altered expression of the DNA repair protein, N‐methylpurine‐DNA glycosylase (MPG), in breast cancer (1998) (40)
HER2--a discussion of testing approaches in the USA. (2001) (40)
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198) (2015) (39)
Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to radiation therapy. (2005) (39)
Monoclonal antibodies and breast cancer. (1986) (38)
Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer (2007) (37)
HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. (2006) (37)
Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3. (1986) (35)
p53 Inactivation Upregulates p73 Expression through E2F-1 Mediated Transcription (2012) (34)
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer (2018) (34)
Tumor‐associated glycoprotein (TAG‐72) expression in ulcerative colitis (1989) (34)
Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo (2017) (32)
Evaluation of in vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit. (1991) (32)
Surface expression of tumor-associated antigens in primary cultured human colonic epithelial cells from carcinomas, benign tumors, and normal tissues. (1985) (32)
p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) (2011) (32)
Pathology of the fallopian tube, broad ligament, peritoneum, and pelvic soft tissues. (1991) (32)
Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications. (1989) (32)
Caspase 3 activation during herpes simplex virus 1 infection. (2006) (29)
Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling (2009) (27)
Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+)advanced non-small cell lung cancer (nsclc): early analysis of e2598 (2001) (27)
Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms (1987) (26)
Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? (2001) (26)
ErbB-2 protein in sera and tumors of breast cancer patients (1998) (26)
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. (2018) (26)
Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases (2017) (26)
p53 analysis in diagnostic pathology. Biologic implications and possible clinical applications. (1993) (25)
The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells (2015) (23)
Applications of immunocytochemistry to clinical cytology. (1987) (23)
Caspase expression profile and functional activity in a panel of breast cancer cell lines. (2007) (22)
COMMENT ON: TUMOR ANGIOGENESIS AS A PROGNOSTIC ASSAY FOR INVASIVE DUCTAL BREAST CARCINOMA. AUTHORS' REPLY (1995) (21)
Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. (1994) (21)
Benign metastasizing pleomorphic adenoma of salivary gland: Diagnosis of bone lesions by fine‐needle aspiration biopsy (1992) (21)
p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma. (1994) (20)
Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity. (1987) (19)
Modulation of human tumor antigen expression. (1987) (18)
Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients (2005) (18)
Detection of adenocarcinoma in peritoneal washings by staining with monoclonal antibody B72.3. (1989) (18)
POST‐HYSTERECTOMY CARCINOMA OF THE FALLOPIAN TUBE MIMICKING A VESICOVAGINAL FISTULA (1992) (17)
ras oncogene p21 expression in hepatocellular carcinoma. (1989) (17)
Tumor-associated antigen TAG-72: Correlation of expression in primary and metastatic breast carcinoma lesions (2005) (16)
Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow (1988) (16)
Immunological characterization of a novel human colon‐associated antigen (CAA) by a monoclonal antibody (1987) (15)
Reactivity of the monoclonal antibody B72.3 with fetal antigen: correlation with expression of TAG-72 in human carcinomas. (1988) (15)
A Revised Staging System for Breast Cancer (2004) (15)
Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells (2018) (14)
Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. (2003) (14)
Paratesticular adenomatoid tumors. The cytologic presentation in fine needle aspiration biopsies. (1989) (13)
The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer (2017) (13)
Immunohistochemical analysis of normal and mutated ras oncogene p21 expression in human pulmonary and pleural neoplasms (1988) (13)
Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. (2015) (12)
Spermatic granuloma. Diagnosis by fine needle aspiration cytology. (1989) (12)
Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem (2020) (12)
Phenotypic heterogeneity of a tumor-associated antigen in adenocarcinomas of the colon and their metastases as demonstrated by monoclonal antibody B72.3. (1986) (12)
Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice. (2004) (11)
Tumor targeting with monoclonal antibody B72.3: experimental and clinical results. (1990) (11)
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. (2008) (10)
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers (2016) (9)
Prognostic factors in breast cancer: Integrating the cytology laboratory (1992) (9)
Expression of ras oncogene p21 during human fetal development as determined by monoclonal antibodies RAP-5, Y13-259, and DWP (1988) (9)
Enhancement of tumor‐associated glycoprotein‐72 antigen expression in hormone‐related ovarian serous borderline tumors (1991) (8)
pS2 expression in primary breast carcinomas: Relationship to clinical and histological features and survival (2005) (7)
Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148). (2009) (7)
Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198) (2001) (6)
HER2 testing: laboratory, technical and clinical considerations. (2000) (6)
Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. (2017) (6)
Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC (2021) (6)
Metformin Activity against Breast Cancer: Mechanistic Differences by Molecular Subtype and Metabolic Conditions (2020) (6)
Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers (2020) (6)
Radiolocalization of colon cancer with I-131 B72. 3 monoclonal antibody (1985) (6)
Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells (2017) (6)
TAG-72 as a Tumor Marker (1992) (5)
Pathology and genetic testing (1997) (5)
Pathology in gynecology and obstetrics (ed 4) (1994) (5)
ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR+HER2+ breast cancer patients (2020) (5)
16 – Colon Carcinoma Cell Population as Defined by Monoclonal Antibodies (1990) (4)
Understanding the age dependency of breast cancer biomarkers. (2003) (4)
Abstract 2967: Metformin selectively targets tumor initiating cells in erbb-2 overexpressing breast cancer models (2014) (4)
AIDS-related Cryptococcus neoformans choroiditis (2020) (3)
Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C) and Herceptin (H) in HER2/neu (+) advanced NSCLC: Preliminary analysis (2000) (3)
Biodistribution of monoclonal antibody B72. 3(I-131) in colon cancer patients (1985) (3)
Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours. (1991) (3)
Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression (Proceedings of the National Academy Sciences of the United States of America (2010) 107, 43 (18616-18621)) (2011) (3)
C-erb B-2 Expression in women with node-positive early breast cancer (1995) (3)
P-628 Trastuzumab in combination with paclitaxel/carboplatin in advanced non-small cell lung cancer: Final report of ECOG 2598 (2003) (2)
Metformin Enhances Trastuzumab Efficacy and Overcomes Resistance in HER2 Type Breast Cancer Cells. (2009) (2)
Epidermal growth factor receptor expression in breast cancer (2005) (2)
PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN HUMAN NERVOUS SYSTEM TUMORS: 34 (1990) (2)
Monoclonal antibody RAP-5 and ras p21 expression. (1988) (2)
Abstract 72: Metformin enhances tumor regression and reduces tumor burden in a preclinical paradigm modeling obesity's impact on postmenopausal breast cancer (2010) (1)
Histochemistry in pathology 2E review (ed 2): M. I. Filipe and B. D. Lake (eds). New York, NY, Churchill Livingstone, 1990, 496 pages (1992) (1)
Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer (2021) (1)
Abstract P1-08-02: Metformin blocks de novo synthesis of cholesterol in triple negative breast cancer cells (2015) (1)
Abstract 4756: Elucidating the role of AR in breast cancer . (2013) (1)
Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. (2009) (1)
Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling (2014) (1)
Predictive Biomarkers and Personalized Medicine p 53 Expression in Node-Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B 9344 Trial ( 159905 ) (2011) (1)
Retrospective analysis of c- erb B-2 and PS2 in early breast cancer before and after local failure (1990) (1)
Thymidilate synthase (TS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), and dihydrofolate reductase (DHFR) as predictive markers of capecitabine efficacy in breast cancer patients. (2009) (1)
Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification: Evaluation According to ASCO/CAP Criteria: Brunelli M, Manfrin E, Martignoni G, et al (Univ of Verona, Italy; et al) Am J Clin Pathol 131:678-682, 2009§ (2009) (1)
The application of monoclonal antibodies in the cytologic evaluation of tumors. (1990) (1)
Abstract P5-10-04: Metformin mediated upregulation of microRNA-193 triggers apoptosis by decreasing fatty acid synthase (2012) (1)
A comparison between DASL and Affymetrix on probing the whole-transcriptome (2016) (1)
Estrogenic Promotion of ErbB 2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB 3 Signaling (2009) (1)
Abstract B20: Role of ErbB3 in tumorigenesis and drug resistance in ErbB2-driven breast cancer (2015) (1)
4–4 p95HER-2 Predicts Worse Outcome in Patients With HER-2-Positive Breast Cancer (2007) (0)
Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer. (2011) (0)
Abstract 4604: PTP4A3 is oncogenic and modulates triple negative breast cancer growth (2014) (0)
Enhanced Expression of e-1la-ras p21 in Human Stomach Adenocarcinomas Defined by Immunoassays Using Monoclonal Antibodies and in Situ Hybridization (2006) (0)
Cytopathology of soft tissue and bone tumors (1990) (0)
Abstract P1-05-01: Characterization of human postpartum breast involution: Implications for young women’s breast cancer (2013) (0)
Response: Re: erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer (1999) (0)
Abstract P5-05-02: Thyroid hormone replacement therapy shortens survival in hormone receptor positive early stage breast cancers (2019) (0)
Thyroid Hormone and Estrogen Promote Endocrine Resistance, Proliferation, Dedifferentiation, and Cancer Stem Cells in Steroid Receptor-Positive Breast Cancers (2021) (0)
COMMENT ON: ERBB-2, P53, AND EFFICACY OF ADJUVANT THERAPY IN LYMPH NODE-POSITIVE BREAST CANCER. AUTHORS' REPLY (1999) (0)
PECAM‐1 and Tumor Metastasis (2007) (0)
Immunology: Basic concepts, diseases, and laboratory methods: J. Helen Cronenberger, J Charles Jenette. Norwalk, CT, Appleton and Lange, 287 pages, $26.95 (1989) (0)
Breast Cancer Risk Associated With Estrogen Receptor Expression in Epithelial Hyperplasia Lacking Atypia and Adjacent Lobular Units (2005) (0)
Helene Smith: A Memorial (2004) (0)
Abstract IA18: Targeting the androgen receptor in multiple breast cancer subtypes (2013) (0)
Tumor and Stem Cell Biology Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer (2012) (0)
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide (2014) (0)
Genistein converts Bcl-2 into a proapoptotic protein in Bcl-2 overexpressing MCF-7 breast cancer cells. (2006) (0)
Abstract P3-04-11: Thyroid hormone up-regulates estrogenic and pro-carcinogenic signaling, inducing a basaloid and more motile phenotype in only steroid receptor positive breast cancer cells (2015) (0)
2-Chlorodeoxyadenosine (2-CDA) and Dexamethasone Induce Apoptosis in Multiple Myeloma (MM) Via Different Mechanisms. (2007) (0)
4–24 Phyllodes Tumors of the Breast: The Role of Pathologic Parameters (2006) (0)
Selective Effects of Glucose, Insulin and Leptin by Molecular Breast Cancer Subtype. (2009) (0)
Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer (2018) (0)
Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer (2013) (0)
Diagnosis of endometrial biopsies and curettings: A practical approach: Michael T. Mazur and Robert J. Kurman. New York, Springer-Verlag, 260 pages, 1995, $79.00 (1996) (0)
Tumor progression and metastasis. UCLA symposia on Molecular and Cellular Biology, vol 78 (1989) (0)
Tumor Associated Antigens and Oncogene Products Defined by Monoclonal Antibodies (1987) (0)
Transabdominal fine-needle aspiration biopsy:Liange-Che Tao, New York, NY, Igaku-Shoin, 1990, 496 pages, $88.75 (1990) (0)
Metabolomics of basal breast carcinomas: a potential target for treatment intervention. (2009) (0)
Prognostic and Predictive Markers in Breast Cancer: Issues Related to Molecular Determinants of Outcome (1998) (0)
Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer (2022) (0)
Potential Clinical Application of a Monoclonal Antibody to a Tumor Associated Glycoprotein (TAG-72) (1985) (0)
3–31 uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues (2007) (0)
Editorial comments: Detection of abnormal p53 protein levels in cytology specimens: Present and future applications (1995) (0)
P5-01-06: Gene Copy Number and Expression of TYMP and TYMS Are Predictive of Outcome in Breast Cancer Patients Treated with Capecitabine. (2011) (0)
Abstract P5-10-05: Novel Mechanisms of Metformin Action in TN Breast Cancer: Upregulation of miRNA 141 and 192, are Associated with a Decrease in TargetsGRB2andMSNInvolved in Signaling and Motility Respectively (2012) (0)
Abstract PS19-18: Metformin exhibits cytotoxicity effects on triple-negative cancer cells via TRAIL-mediated apoptosis (2021) (0)
Practical cytopathology: RW Astarita (ed). New York, NY, Churchill Livingstone, 1989, 472 pages, $110 (1990) (0)
Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients. (2012) (0)
Abstract 1971: ESE-1 controls transformation properties in HER2+ breast cancer cells, and predicts poor prognostic status and survival in breast cancer patients (2015) (0)
Metformin-induced TRAIL Upregulation Promotes Apoptosis in Triple Negative Breast Cancer and Non-small Cell Lung Cancer Cells (2020) (0)
Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells (2018) (0)
Monoclonal Antibodies Generated to a Synthetic Peptide Define Ras Gene Expression at the Single Cell Level in Human Colon and Mammary Carcinomas (1985) (0)
Abstract CN13-04: Obesity, insulin resistance, hyperglycemia, and cancer: A novel role for metformin as an anticancer drug (2010) (0)
Clinical cytopathology and aspiration biopsy (1990) (0)
Infectious and inflammatory diseases and other non-neoplastic disorders (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ann D. Thor?

Ann D. Thor is affiliated with the following schools: